By Stephen Nakrosis

 

Moderna Inc. on Friday said Health Canada has approved its BA.4/BA.5 Omicron-targeting bivalent Covid-19 booster vaccine, mRNA-1273.222.

The company said the authorization is for use as "a booster dose for active immunization against Covid-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older."

Moderna said mRNA-1273.222 is its second bivalent Covid-19 vaccine approved by Health Canada, following the approval of mRNA-1273.214, or SPIKEVAXBivalent, in September.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

November 04, 2022 17:30 ET (21:30 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Moderna Charts.